News articles about Zealand Pharma A/S (NASDAQ:ZEAL) have been trending somewhat positive on Wednesday, according to Accern Sentiment. The research firm scores the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Zealand Pharma A/S earned a media sentiment score of 0.03 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 46.3030692201178 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Zealand Pharma A/S (ZEAL) opened at $12.65 on Wednesday. Zealand Pharma A/S has a 12 month low of $12.54 and a 12 month high of $20.37.
A number of research analysts recently weighed in on ZEAL shares. Zacks Investment Research raised shares of Zealand Pharma A/S from a “hold” rating to a “buy” rating and set a $17.00 price target on the stock in a research note on Wednesday, November 15th. Needham & Company LLC started coverage on shares of Zealand Pharma A/S in a research note on Tuesday, September 5th. They issued a “buy” rating and a $26.00 price target on the stock. Morgan Stanley started coverage on shares of Zealand Pharma A/S in a research note on Tuesday, September 5th. They issued an “overweight” rating and a $28.00 price target on the stock. Guggenheim started coverage on shares of Zealand Pharma A/S in a research note on Tuesday, September 5th. They issued a “buy” rating and a $28.00 price target on the stock. Finally, Goldman Sachs Group initiated coverage on shares of Zealand Pharma A/S in a research note on Wednesday, September 27th. They issued a “buy” rating on the stock. Five analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and a consensus price target of $24.75.
About Zealand Pharma A/S
Zealand Pharma A/S, a biotech company, engages in the discovery, design, and development of novel peptide-based medicines in Denmark. The company markets Lixisenatide, a once-daily prandial GLP-1 peptide receptor agonist for the treatment of type 2 diabetes under the Adlyxin and Lyxumia names; and Soliqua 100/33/Suliqua, a combination of lixisenatide and insulin glargine, and a GLP-1 receptor agonist for the treatment of type 2 diabetes.
Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.